Disease · MONDO_0019340
Targets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 36
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ABL1 | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| TGFB1 | Transforming growth factor beta-1 proprotein | 2 | Transforming growth factor beta-1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7040 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 1 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| F2 | Prothrombin | 1 | Thrombin inhibitor | Phase 1 | https://conductscience.org/library/genes/2147 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor 1 | 1 | Interferon-alpha/beta receptor alpha chain antagonist | Phase 1 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 2 | https://conductscience.org/library/genes/3566 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 1 | Interleukin-6 receptor alpha subunit antagonist | Phase 1/2 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 1 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| LPAR1 | Lysophosphatidic acid receptor 1 | 1 | Lysophosphatidic acid receptor Edg-2 antagonist | Phase 2 | https://conductscience.org/library/genes/1902 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 2/3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 1 | Platelet-derived growth factor receptor beta inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Phase 2 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Phase 2 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| PTGIR | Prostacyclin receptor | 1 | Prostanoid IP receptor agonist | Phase 2 | https://conductscience.org/library/genes/5739 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019340/targets